Loading…
MDXH
MDxHealth SA
NASDAQ· Healthcare· Diagnostics & Research· CUSIP B5950S113
$0.72-0.11%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $68.77M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.71
- ROE
- —
- Profit margin
- -32.74%
- Revenue growth
- +2.30%
- Beta
- -501440.84
- 52-week high
- $5.33
- 52-week low
- $0.40
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -93.8% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.57 | $2.37 | $3.94 | $6.61 | |
| P/S | 1.6x | 1.7x | 1.3x | 1.5x | 2.9x |
| P/B | 11.6x | — | 7.9x | 14.9x | 11.6x |
| EPS | -$0.67 | -$1.16 | -$1.66 | -$2.80 | |
| Profit margin | -51.84% | -31.07% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CSBRChampions Oncology Inc | $4.93 | — | 17.4x | — | -29.97% | $68.5M |
| XBITXBiotech Inc. | $2.27 | — | 0.5x | — | -29.94% | $69.21M |
| PLRXPliant Therapeutics Inc | $1.13 | — | 0.5x | — | -50.29% | $69.66M |
| SPROSpero Therapeutics, Inc. | $1.20 |
About the company
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
- 364
- Herstal, Belgium
Company description provided by Yahoo Finance.